Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

TAKEDA PHARMACEUTICAL COMPANY LIMITED

(4502)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Takeda says it may double imports of Moderna shots to help accelerate Japan vaccination

05/11/2021 | 05:46am EDT
Takeda Pharmaceutical Co's logo is seen at its new headquarters in Tokyo

TOKYO (Reuters) - Takeda Pharmaceutical Co on Tuesday said it may double imports of Moderna Inc's COVID-19 vaccine to help Japan speed up COVID-19 inoculation efforts that have trailed most wealthy countries.

Japan's biggest drugmaker is handling the imports, and discussions are underway with the government to double shipments to 100 million, Takeda CEO Christophe Weber said.

"Japan is behind. So our goal now is to really support an acceleration of the vaccination," Weber said in a conference call after the company released full-year earnings results.

The company had reported positive interim results from a domestic trial of the Moderna shot, and Weber said he expected approval to come "very soon".

The COVID-19 pandemic has defined much of Takeda's activities in the past 12 months. This time last year, the company was promoting a plasma treatment for the disease, which ultimately failed in clinical trials.

Takeda is also handling domestic approval and production of 250 million doses of Novavax Inc's vaccine candidate. The Japanese government wants to use 150 million, with the remainder being dispatched elsewhere, Weber said.

For the year ended on March 31, Takeda reported a five-fold increase in operating profit versus the previous year, driven by sales of its Entyvio colitis treatment and other mainstay drugs.

Operating profit was 509 billion yen ($4.68 billion), compared with earlier guidance of 434 billion yen and a consensus estimate of 567 billion yen from a Refinitiv poll of 14 analysts.

Takeda also exceeded its goal for asset sales this year to reduce debt following a $59 billion purchase of Shire Plc in 2019. It has off-loaded about $12.9 billion in assets so far, mostly in over-the-counter and consumer goods, as part of a renewed focus on prescription drugs.

Among the biggest divestitures was Takeda's 227.7 billion yen sale of its Japanese consumer healthcare company to funds controlled by the Blackstone Group Inc.

Takeda's shares slipped 0.2% ahead of the results versus a 3.1% slide in the market overall.

($1 = 108.8600 yen)

(Reporting by Rocky Swift; Editing by Kim Coghill, Jane Merriman and Tom Hogue)


© Reuters 2021
Stocks mentioned in the article
ChangeLast1st jan.
BLACKSTONE INC. 0.33% 135.04 Delayed Quote.108.36%
MODERNA, INC. 1.42% 440.65 Delayed Quote.321.80%
NOVAVAX, INC. 2.14% 237.27 Delayed Quote.112.78%
TAKEDA PHARMACEUTICAL COMPANY LIMITED 1.53% 3780 End-of-day quote.0.67%
All news about TAKEDA PHARMACEUTICAL COMPANY LIMITED
02:02pTAKEDA PHARMACEUTICAL : Continues to Advance Growth Strategy with Sale Of Non-Co..
PU
10:27aTAKEDA PHARMACEUTICAL : EXKIVITY (mobocertinib) Approved by U.S. FDA as the Firs..
AQ
10:12aTHERMO FISHER SCIENTIFIC : FDA Approves Tissue-Based NGS Companion Diagnostic fo..
AQ
09/15TAKEDA PHARMACEUTICAL : U.S. FDA approves Takeda's lung cancer therapy
RE
09/15TAKEDA PHARMACEUTICAL : U.S. FDA approves Takeda's lung cancer therapy
RE
09/15TAKEDA PHARMACEUTICAL : Exkivity Wins FDA Approval for Treatment of Lung Cancer ..
MT
09/15TAKEDA PHARMACEUTICAL : EXKIVITY™ (mobocertinib) Approved by U.S. FDA as t..
BU
09/15Food and Drug Administration Approves Takeda’s EXKIVITY™ (Mobocertinib) for t..
CI
09/13Takeda eyes vaccine business growth as dengue, COVID-19 shots progress - CEO
RE
09/13TAKEDA PHARMACEUTICAL : Novavax Statement on Takeda Agreement to Provide 150 Mil..
AQ
More news
Analyst Recommendations on TAKEDA PHARMACEUTICAL COMPANY LIMITED
More recommendations
Financials
Sales 2022 3 387 B 30 838 M 30 838 M
Net income 2022 253 B 2 307 M 2 307 M
Net Debt 2022 3 472 B 31 620 M 31 620 M
P/E ratio 2022 23,6x
Yield 2022 4,76%
Capitalization 5 944 B 54 198 M 54 128 M
EV / Sales 2022 2,78x
EV / Sales 2023 2,65x
Nbr of Employees 47 099
Free-Float 99,3%
Chart TAKEDA PHARMACEUTICAL COMPANY LIMITED
Duration : Period :
Takeda Pharmaceutical Company Limited Technical Analysis Chart | 4502 | JP3463000004 | MarketScreener
Technical analysis trends TAKEDA PHARMACEUTICAL COMPANY LIMITED
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 3 780,00 JPY
Average target price 4 844,67 JPY
Spread / Average Target 28,2%
EPS Revisions
Managers and Directors
Christophe Weber President, CEO & Representative Director
Constantine Saroukos Chief Financial Officer & Director
Andrew S. Plump Director, Research & Development President
Michael E. Mendelsohn Chief Medical & Scientific Officer
Norimasa Takeda Chief Accounting Officer & Corporate Controller
Sector and Competitors
1st jan.Capi. (M$)
TAKEDA PHARMACEUTICAL COMPANY LIMITED0.67%53 518
JOHNSON & JOHNSON5.11%435 465
ROCHE HOLDING AG11.23%327 497
PFIZER, INC.21.46%251 011
NOVO NORDISK A/S49.16%231 607
ELI LILLY AND COMPANY38.43%211 895